Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor
Quinolylpropylpiperidine derivatives of general formula (I) in which R 1a is hydrogen, halogen, hydroxyl, amino, alkylamino, dialkylamino, hydroxyamino, alkoxyamino or alkylalkoxyamino and R 1b is hydrogen, or R 1a and R 1b form an oxo, R 2 is carboxyl, carboxymethyl or hydroxymethyl, R 3 is alkyl either substituted with phenylthio optionally substituted with halogen, hydroxyl, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkoxycarbonyl, cyano or amino, or with cycloalkylthio (3 to 7 members) optionally substituted with halogen or trifluoromethyl, or with heteroarylthio (5 to 6 members and 1 to 4 heteroatoms chosen from N, O and S), optionally substituted with halogen, hydroxyl, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkoxycarbonyl, cyano or amino or R 3 is propargyl substituted with phenyl or heteroaryl as defined above, R 4 is alkyl, alkenyl-CH 2 — or alkynyl-CH 2 —, cycloalkyl or cycloalkylalkyl, in their various isomeric forms, separate or as mixtures, and also their salts, their preparation process and intermediates and the compositions containing them. These novel derivatives are potent antibacterial agents.
1. A compound of the formula (I):
wherein:
R 1a is hydrogen, halogen, hydroxyl, amino, alkylamino, dialkylamino, hydroxyamino, alkoxyamino or alkylalkoxyamino; and
R 1b is hydrogen; or
R 1a and R 1b form an oxo group;
R 2 is carboxyl, carboxymethyl or hydroxymethyl;
R 3 is C 1-6 alkyl substituted with phenylthio, C 3-7 cycloalkylthio or 5- to 6-membered heteroarylthio; or propargyl substituted with phenyl, C 3-7 cycloalkyl or 5- to 6-membered heteroaryl;
wherein said heteroaryl is having 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur; and
wherein said phenyl or said heteroaryl is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, alkyl, alkyloxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkyloxycarbonyl, cyano and amino; and
wherein said cycloalkyl is optionally substituted with one or more substituents chosen from halogen and trifluoromethyl; and
R 4 is C 1-6 alkyl, C 2-6 alkenyl-CH 2 — or C 2-6 alkynyl-CH 2 —, C 3-8 cycloalkyl or C 3-8 cycloalkylalkyl; or
an isomer, an enantiomer, a diastereoisomer or a mixture thereof, or a pharmaceutically acceptable salt thereof.
2. The compound as set forth in claim 1 , wherein R 1a is hydroxyl and R 1b is hydrogen.
3. The compound as set forth in claim 1 , wherein R 1a and R 1b form an oxo group.
4. The compound as set forth in claim 1 , wherein R 4 is C 1-6 alkyl.
5. The compound as set forth in claim 1 , wherein R 2 is carboxyl.
6. The compound as set forth in claim 1 , wherein R 3 is C 1-6 alkyl substituted with an optionally substituted phenylthio, cycloalkylthio or heteroarylthio.
7. The compound as set forth in claim 6 , wherein R 3 is ethyl substituted with thienylthio or phenylthio substituted with halogen or cyclohexylthio or cyclopentylthio.
8. The compound as set forth in claim 1 , which is selected from the group consisting of:
4-[3-hydroxy-3-(3-chloro-6-methoxyquinolin-4-yl)-propyl]-1-[2-(2,5-difluorophenyl-sulfanyl)ethyl]piperidine-3-carboxylic acid; and
4-[3-hydroxy-3-(3-chloro-6-methoxyquinolin-4-yl)-propyl]-1-[2-(2-thienylsulfanyl)ethyl]piperidine-3-carboxylic acid; or
an isomer, an enantiomer, a diastereoisomer or a mixture thereof, or a pharmaceutically acceptable salt thereof.
9. A process for preparing a compound of formula (I) as set forth in claim 1 comprising condensing R 3 —X with a compound of formula (II):
wherein R 4 is as defined in claim 1 ;
R′ 1a is hydrogen or hydroxyl; and
R 1b is hydrogen; or
R′ 1a and R 1b form an oxo group; and
R′ 2 is protected carboxyl or carboxymethyl;
to obtain a compound of formula (III):
wherein R′ 1a , R 1b , R′ 2 , R 3 and R 4 are as defined above; and optionally
treating the compound of formula (III) in which R′ 1a is hydroxyl and R 1b is hydrogen with a halogenating agent; or optionally
oxidizing the compound of formula (III) in which R′ 1a is hydroxyl and R 1b is hydrogen to an oxo group; and
converting said oxo group to hydroxyimino or alkoxyimino group;
to obtain a compound of formula (IV):
wherein R′ 2 , R 3 and R 4 are as defined above; and
R 5 is hydrogen or alkyl; and
reducing the compound of formula (IV) in which R 5 is hydrogen to the corresponding amine; and optionally,
alkylating said amine to a monoalkylated or dialkylated amine; or optionally
reducing the compound of formula (IV) in which R 5 is hydrogen to a hydroxylamine, or
reducing the compound of formula (IV) in which R 5 is an alkyl to an alkoxyamine; and optionally
alkylating said alkoxyamine to obtain the corresponding compound in which R 1a is alkylalkoxyamino; and
converting R′ 2 to carboxyl or carboxymethyl; and optionally
reducing said carboxyl or protected carboxyl compound to hydroxymethyl compound; and optionally
converting said hydroxymethyl compound to carboxymethyl compound; and optionally
separating the isomers, and removing the acid-protecting group; and optionally
converting said compound to a suitable salt.
10. The process as set forth in claim 9 , wherein the compound of formula (II), in which R′ 1a is hydroxyl, is prepared by oxidation in a basic medium of a corresponding compound for which R′ 1a and R 1b are hydrogen, the amine functional group of the piperidine is protected and R′ 2 is as defined in claim 9 .
11. The process as set forth in claim 9 , wherein the compound of formula (II) in which R′ 1a and R 1b form an oxo group is prepared by oxidation of a corresponding compound of formula (II) in which R′ 1a is a hydroxyl, which is obtained as described in claim 10 .
12. The process as set forth in claim 9 , wherein the compound of formula (II) in which R′ 2 represents a protected carboxymethyl, and R′ 1a and R 1b are hydrogen, is prepared by condensing a suitable phosphorous ylide with a compound of formula (IX):
wherein Rz is an amino-protecting group; to obtain a compound of formula (VIII):
wherein Rz is as defined above and R″ 2 is a protected carboxyl; and
condensing said compound of formula (VIII) with a compound of formula (VII):
wherein R 4 is defined as in claim 1 and Hal represents an iodine or bromine atom;
to obtain a compound of formula (VI):
wherein R″ 2 and Rz are as defined above; and
subjecting said compound of formula (VI) to a selective hydrogenation; and optionally deprotecting, where appropriate, the amino group of the piperidine.
13. The process as set forth in claim 12 , wherein the compound of formula (II) in which R′ 2 is protected carboxyl is prepared by
subjecting a compound of formula (II) in which R′ 2 is protected carboxymethyl to a reduction to obtain a compound of formula (II) in which R′ 2 is hydroxyethyl;
converting said hydroxyethyl compound to a p-toluenesulfonyloxyethyl derivative; and
converting said derivative to a vinyl derivative by an elimination reaction; and
oxidizing said vinyl derivative and protecting thus obtained carboxyl to obtain compound of formula (II) in which R′ 2 is protected carboxyl.
14. The process as set forth in claim 9 , wherein the compound of formula (II), in which R′ 1a and R 1b are hydrogen atoms, is prepared by allyation of the keto ester of general formula (XIV):
wherein R′ 2 is as defined in claim 8 and Rz is as defined in claim 12 , to obtain a derivative of general formula (XIII):
wherein R′ 2 and Rz are as defined above, which is reacted with an alkyl oxalyl halide to obtain a derivative of general formula (XII):
wherein R″ represents an alkyl and R′ 2 and Rz are as defined above, which is subjected to a deoxygenation reaction, to obtain a derivative of general formula (X):
in which R′ 2 and Rz are as defined above, which is condensed with a quinoline derivative of general formula (VII) as defined in claim 10 , to obtain a derivative of general formula (XI):
and then the amino-protecting radical Rz is removed.
15. The process as set forth in claim 9 wherein the compound formed is 4-[3-hydroxy-3-(3-chloro-6-methoxyquinolin-4-yl)-propyl]-1-[2-(2,5-difluoro-phenylsulfanyl)ethyl]piperidine-3-carboxylic acid.
16. The process as set forth in claim 9 wherein the compound formed is 4-[3-hydroxy-3-(3-chloro-6-methoxyquinolin-4-yl)-propyl]-1-[2-(2-thienylsulfanyl))ethyl]piperidine-3-carboxylic acid.
17. A pharmaceutical composition comprising therapeutically effective amount of a compound of formula (I) as set forth in claim 1 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.
18. A compound of formula (II):
wherein R 4 is as defined in claim 1 , either R′ 1a is hydrogen or hydroxyl and R 1b is hydrogen or R′ 1a and R 1b form an oxo group and R′ 2 is protected carboxyl or carboxymethyl.
19. A compound of formula (A):
wherein R 1a , R 1b , R 3 and R 4 are as defined in claim 1 and R′ 2 is protected carboxyl or carboxymethyl.
20. A compound of formula (IV):
wherein R 3 and R 4 are as defined in claim 1 and R′ 2 is protected carboxyl or carboxymethyl and R 5 is hydrogen or alkyl.
21. A compound of formula (VI):
wherein R 4 is as defined in claim 1 and R″ 2 is protected carboxyl and Rz is an amino-protecting group.
22. A compound of formula (XI):
wherein R 4 is as defined in claim 1 , R′ 2 is protected carboxyl or carboxymethyl and Rz is an amino-protecting group.
23. A method of treatment of a bacterial infection in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula (I) as set forth in claim 1 or a pharmaceutically acceptable salt thereof.
24. The method as set forth in claim 23 wherein said bacterial infection is caused by gram (+) bacteria.
25. The method as set forth in claim 23 wherein said bacterial infection is staphylococcic infection.
26. The method as set forth in claim 23 wherein said staphylococcic infection is selected from the group consisting of staphylococcal septicemias, malignant staphylococcic infections of the face or skin, pyoderma, septic or suppurant wounds, anthrax, phlegmons, erysipelas, acute primary or post-influenza staphylococcic infections, bronchopneumonias and pulmonary suppurations.
27. The method as set forth in claim 23 wherein said bacterial infection is colibacilloses and related infections, proteus infection, klebsiella infection, salmonella infection, and infection caused by gram (−) bacteria.